杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2017/04/27 | 2,314 | 2,314 | 2,291 | 2,301 | -14 | -0.6% | 137,600 |
2017/04/26 | 2,326 | 2,332 | 2,304 | 2,315 | +11 | +0.5% | 111,500 |
2017/04/25 | 2,302 | 2,308 | 2,274 | 2,304 | -5 | -0.2% | 236,400 |
2017/04/24 | 2,293 | 2,319 | 2,279 | 2,309 | +44 | +1.9% | 130,900 |
2017/04/21 | 2,270 | 2,275 | 2,251 | 2,265 | +17 | +0.8% | 138,300 |
2017/04/20 | 2,255 | 2,270 | 2,244 | 2,248 | -21 | -0.9% | 139,500 |
2017/04/19 | 2,252 | 2,281 | 2,251 | 2,269 | +6 | +0.3% | 273,300 |
2017/04/18 | 2,287 | 2,287 | 2,255 | 2,263 | -25 | -1.1% | 288,000 |
2017/04/17 | 2,290 | 2,291 | 2,270 | 2,288 | +10 | +0.4% | 147,200 |
2017/04/14 | 2,310 | 2,313 | 2,274 | 2,278 | -35 | -1.5% | 78,000 |
2017/04/13 | 2,303 | 2,325 | 2,290 | 2,313 | -2 | -0.1% | 162,300 |
2017/04/12 | 2,309 | 2,320 | 2,294 | 2,315 | -17 | -0.7% | 113,500 |
2017/04/11 | 2,316 | 2,339 | 2,310 | 2,332 | ±0 | ±0% | 136,100 |
2017/04/10 | 2,355 | 2,365 | 2,318 | 2,332 | +2 | +0.1% | 155,200 |
2017/04/07 | 2,330 | 2,354 | 2,318 | 2,330 | +13 | +0.6% | 240,300 |
2017/04/06 | 2,374 | 2,389 | 2,301 | 2,317 | -57 | -2.4% | 255,000 |
2017/04/05 | 2,383 | 2,406 | 2,364 | 2,374 | -14 | -0.6% | 257,200 |
2017/04/04 | 2,368 | 2,408 | 2,362 | 2,388 | -1 | ±0% | 231,400 |
2017/04/03 | 2,352 | 2,408 | 2,352 | 2,389 | +38 | +1.6% | 187,000 |
2017/03/31 | 2,412 | 2,412 | 2,351 | 2,351 | -30 | -1.3% | 153,800 |
2017/03/30 | 2,409 | 2,426 | 2,381 | 2,381 | -26 | -1.1% | 149,900 |
2017/03/29 | 2,417 | 2,417 | 2,390 | 2,407 | -26 | -1.1% | 129,500 |
2017/03/28 | 2,424 | 2,440 | 2,412 | 2,433 | +40 | +1.7% | 157,900 |
2017/03/27 | 2,380 | 2,417 | 2,380 | 2,393 | -21 | -0.9% | 116,900 |
2017/03/24 | 2,384 | 2,420 | 2,370 | 2,414 | +15 | +0.6% | 123,200 |
2017/03/23 | 2,397 | 2,406 | 2,378 | 2,399 | +5 | +0.2% | 97,400 |
2017/03/22 | 2,392 | 2,418 | 2,391 | 2,394 | -45 | -1.8% | 103,300 |
2017/03/21 | 2,425 | 2,452 | 2,425 | 2,439 | +14 | +0.6% | 137,400 |
2017/03/17 | 2,421 | 2,437 | 2,403 | 2,425 | -16 | -0.7% | 231,600 |
2017/03/16 | 2,442 | 2,458 | 2,430 | 2,441 | -23 | -0.9% | 129,200 |
2017/03/15 | 2,444 | 2,474 | 2,431 | 2,464 | +1 | ±0% | 97,000 |
2017/03/14 | 2,472 | 2,503 | 2,462 | 2,463 | ±0 | ±0% | 119,400 |
2017/03/13 | 2,449 | 2,473 | 2,446 | 2,463 | +14 | +0.6% | 126,900 |
2017/03/10 | 2,419 | 2,455 | 2,419 | 2,449 | +66 | +2.8% | 151,700 |
2017/03/09 | 2,416 | 2,421 | 2,376 | 2,383 | -6 | -0.3% | 124,200 |
2017/03/08 | 2,387 | 2,389 | 2,356 | 2,389 | -20 | -0.8% | 218,200 |
2017/03/07 | 2,402 | 2,415 | 2,397 | 2,409 | +9 | +0.4% | 93,900 |
2017/03/06 | 2,397 | 2,408 | 2,384 | 2,400 | -34 | -1.4% | 124,100 |
2017/03/03 | 2,427 | 2,452 | 2,427 | 2,434 | -5 | -0.2% | 89,200 |
2017/03/02 | 2,464 | 2,480 | 2,437 | 2,439 | +11 | +0.5% | 197,900 |
2017/03/01 | 2,398 | 2,444 | 2,397 | 2,428 | +57 | +2.4% | 234,600 |
2017/02/28 | 2,383 | 2,412 | 2,371 | 2,371 | ±0 | ±0% | 179,000 |
2017/02/27 | 2,338 | 2,378 | 2,329 | 2,371 | ±0 | ±0% | 207,800 |
2017/02/24 | 2,360 | 2,376 | 2,343 | 2,371 | -3 | -0.1% | 266,500 |
2017/02/23 | 2,410 | 2,410 | 2,349 | 2,374 | -50 | -2.1% | 258,000 |
2017/02/22 | 2,379 | 2,433 | 2,372 | 2,424 | +44 | +1.8% | 264,100 |
2017/02/21 | 2,368 | 2,381 | 2,346 | 2,380 | +21 | +0.9% | 106,100 |
2017/02/20 | 2,345 | 2,369 | 2,324 | 2,359 | -5 | -0.2% | 149,800 |
2017/02/17 | 2,356 | 2,379 | 2,342 | 2,364 | +8 | +0.3% | 115,800 |
2017/02/16 | 2,366 | 2,377 | 2,341 | 2,356 | -5 | -0.2% | 195,200 |
1851~
1900
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム